These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3588346)

  • 1. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects.
    Riekkinen P; Legros JJ; Sennef C; Jolkkonen J; Smitz S; Soininen H
    Peptides; 1987; 8(2):261-5. PubMed ID: 3588346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects.
    Westenberg HG; Hijman R; Wiegant VM; Laczi F; Van Ree JM
    Peptides; 1994; 15(6):1101-4. PubMed ID: 7991455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology.
    van Bree JB; Tio S; de Boer AG; Danhof M; Verhoef JC; Breimer DD
    Pharm Res; 1990 Mar; 7(3):293-8. PubMed ID: 2339105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog.
    Ang VT; Jenkins JS
    J Endocrinol; 1982 Jun; 93(3):319-25. PubMed ID: 7086325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced monoaminergic neurotransmission by desglycinamide-arginine-vasopressin in human subjects.
    Jolkkonen J; Lehtinen M; Soininen H; Sennef C; Riekkinen P
    Neurosci Lett; 1987 May; 76(3):312-5. PubMed ID: 2438607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia.
    Peabody CA; Thiemann S; Pigache R; Miller TP; Berger PA; Yesavage J; Tinklenberg JR
    Neurobiol Aging; 1985; 6(2):95-100. PubMed ID: 3895014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of desglycinamide-arginine-vasopressin (DGAVP) on memory in patients with korsakoff's syndrome.
    Laczi F; Van Ree JM; Balogh L; Szász A; Járdánházy T; Wágner A; Gáspár L; Valkusz Z; Dobranovics I; Szilárd J
    Acta Endocrinol (Copenh); 1983 Oct; 104(2):177-82. PubMed ID: 6637330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of desglycinamide-(Arg8)-vasopressin (DGAVP) on the acquisition of free-choice alcohol drinking in rhesus monkeys.
    Kornet M; Goosen C; Ribbens LG; Van Ree JM
    Alcohol Clin Exp Res; 1991 Feb; 15(1):72-9. PubMed ID: 2024735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of acute and chronic treatment with desglycinamide-[Arg8]vasopressin in young male and female volunteers.
    Bruins J; Hijman R; Van Ree JM
    Peptides; 1995; 16(2):179-86. PubMed ID: 7784246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of DGAVP on verbal memory.
    Pietrowsky R; Fehm-Wolfsdorf G; Born J; Fehm HL
    Peptides; 1988; 9(6):1361-6. PubMed ID: 3247253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma.
    Bohnen NI; Twijnstra A; Jolles J
    Neurology; 1993 Jan; 43(1):103-6. PubMed ID: 8423870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate.
    Verhoef J; van den Wildenberg HM; van Nispen JW
    J Endocrinol; 1986 Sep; 110(3):557-62. PubMed ID: 3760747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention of ethanol tolerance by desglycinamide-arginine-vasopressin occurs in the absence of changes in hippocampal serotonin synthesis.
    Speisky MB; Kalant H
    Alcohol Alcohol Suppl; 1987; 1():455-9. PubMed ID: 3426715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does DGAVP influence memory, attention and mood in young healthy men?
    Snel J; Taylor J; Wegman M
    Psychopharmacology (Berl); 1987; 92(2):224-8. PubMed ID: 3110845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects.
    Bruins J; Kumar A; Schneider-Helmert D
    Neuropsychobiology; 1990; 23(2):82-8. PubMed ID: 2077437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of AVP and DGAVP on the exploratory activity of rats.
    Skopková J; Lát J; Dvorská I; Hrbas P; Radil T
    Peptides; 1987; 8(5):785-90. PubMed ID: 3432126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in cognitively impaired patients.
    Tinklenberg JR; Pigache R; Berger PA; Kopell BS
    Psychopharmacol Bull; 1982 Oct; 18(4):202-4. PubMed ID: 7156291
    [No Abstract]   [Full Text] [Related]  

  • 18. Vasopressin(1-8) (des-glycinamide9-[Arg8]vasopressin) is an endogenous peptide present in rat plasma.
    Laczi F; Burbach JP; Van der Kleij AA; De Wied D; Wiegant VM
    Peptides; 1991; 12(2):329-32. PubMed ID: 2067985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin-like peptides retain ethanol tolerance in the absence of changes in serotonin synthesis in limbic structures.
    Speisky MB; Kalant H
    Pharmacol Biochem Behav; 1986 Oct; 25(4):797-803. PubMed ID: 2431418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of specific antisera against 9-desglycinamide-8-arginine vasopressin by site-specific immunization.
    van Bree JB; van Nispen JW; Verhoef JC; Breimer DD
    J Pharm Sci; 1991 Jan; 80(1):46-9. PubMed ID: 2013849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.